Free Trial

Baudax Bio (BXRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
310,800 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
Dividend Yield
Price Target
BXRX stock logo

About Baudax Bio Stock (NASDAQ:BXRX)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Baudax Bio (BXRX) Gets a Hold from Noble Financial
Noble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)
Baudax Improves on Q1 Results
Recap: Baudax Bio Q1 Earnings
Why Is Baudax Bio (BXRX) Stock Down 52% Today?
See More Headlines
Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.27 million
Book Value
($14.93) per share


Free Float
Market Cap
$1.14 million
Not Optionable
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Geraldine A. Henwood Ph.D. (Age 72)
    President, CEO & Director
    Comp: $633.25k
  • Mike Choi
    Vice President of Financial Planning & Analysis
  • Ms. Natalie McAndrew (Age 53)
    Consultant & Principle Accounting Officer
  • Dr. Chan Kim Yong Ph.D. (Age 50)
    Chief Scientific Officer & Director

BXRX Stock Analysis - Frequently Asked Questions

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) issued its quarterly earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share for the quarter, topping analysts' consensus estimates of ($2.04) by $0.55.

When did Baudax Bio's stock split?

Shares of Baudax Bio reverse split on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

This page (NASDAQ:BXRX) was last updated on 5/26/2024 by Staff

From Our Partners